It was shown that only one genetic aberration, the BCR-ABL translocation, is central to the pathogenesis of chronic myeloid leukaemia, which led to the development and subsequent approval of imatinib, a BCR-ABL kinase inhibitor for treating this cancer type [8]. This evidence concerns the gene ABL1 and cancer.